Enspryng (satralizumab), new treatment for rare autoimmune disease of nerve cells
EMA has recommended granting a marketing authorisation in the European Union (EU) for Enspryng (satralizumab) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adults and